Clinical trial
Optimal Length of Treatment Continuation With Olanzapine After Remission of…
NCT00191997 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191997 |
|---|---|
| Title | Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode |
| Official title | Optimal Treatment Duration With Olanzapine Following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Olanzapine |
| Enrollment | 180 |
| Start date | Oct 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 25, 2006 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: